Compare GLBS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | RVPH |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | Greece | United States |
| Employees | N/A | 14 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 29.2M |
| IPO Year | 2010 | N/A |
| Metric | GLBS | RVPH |
|---|---|---|
| Price | $2.15 | $0.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $3.14 |
| AVG Volume (30 Days) | 67.4K | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.03 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.20 |
| 52 Week High | $2.12 | $1.47 |
| Indicator | GLBS | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 68.96 | 29.12 |
| Support Level | $1.06 | N/A |
| Resistance Level | N/A | $0.31 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 100.00 | 15.18 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.